# LIGHTHOUSE (NCT04649060)

> Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04649060
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Oncopeptides AB
- Conditions: Relapsed Multiple Myeloma; Relapsed-Refractory Multiple Myeloma
- Interventions: Melflufen; Dexamethasone; Daratumumab
- Enrollment: 54
- Primary outcome: Progression Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=lighthouse-nct04649060